More on JNJ
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $255.56 |
|
|||
| Open | $254.43 | ||||
| 52 Wk High | $126.07 | ||||
| 52 Wk Low | $94.28 | ||||
| Day High | $255.56 | ||||
| Day Low | $251.50 | ||||
| P/E | 52.76 | ||||
| EPS | $4.81 | ||||
| Volume | 8,852,961 | ||||
- Johnson & Johnson's Tremfya shows fistula remission at 48 weeks in Crohn's
- Johnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula
- Johnson & Johnson (JNJ) PT Raised to $287 at Wells Fargo
- Johnson & Johnson (JNJ) PT Raised to $270 at Bernstein SocGen Group
- Johnson & Johnson (JNJ) PT Lowered to $292 at Morgan Stanley
- Johnson & Johnson (JNJ) PT Lowered to $280; RBC Capital: 'Excessive Sell-Off Creates Defensive Opportunity'
- Johnson & Johnson (JNJ) PT Lowered to $275 at Wells Fargo
- Johnson & Johnson (JNJ) PT Raised to $275 at BofA Securities
- Form 8-K JOHNSON & JOHNSON For: Oct 13
- Johnson & Johnson beats estimates, raises 2026 guidance
Entities mentioned with JNJ
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Twitter | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
